美国Accumetrics  
Accumetrics 致力于通过提供业界领先且广泛可用的快速评估血小板功能的诊断检测方法，来促进医学界对血小板功能的了解，并提高对正在接受抗血小板治疗的患者的护理质量。

Accumetrics 的 VerifyNow System 是帮助医生判定个体患者对多种抗血小板药物反应的首个快速且易于使用的平台。VerifyNow System 适用于各种主要的抗血小板药，包括获得 FDA 批准的阿司匹林产品、P2Y12 抑制剂（如 prasugrel (Effient) 和 clopidogrel (Plavix)）、以及 GP IIb/IIIa 抑制剂（如 ReoPro(R) 和 Integrilin(R)），提供了一种可以帮助医生做出明智治疗决定的宝贵工具。

Accumetrics is at the forefront of revolutionizing the way doctors manage the tens of millions of patients who take antiplatelet drugs to prevent heart attack, stroke and other potentially life-threatening cardiovascular events.

Accumetrics is a privately-held company based in San Diego, California. The company develops, manufactures, and markets the VerifyNow® System, a comprehensive suite of tests for the assessment of platelet response to antiplatelet therapies. The tests are fully automated and easy-to-use allowing physicians an accurate way to assess platelet response to optimize the effectiveness of antiplatelet therapies, and to guide treatment decisions in patients who may be at risk of a life threatening thrombosis event or bleeding complication.